-+ 0.00%
-+ 0.00%
-+ 0.00%

Abbott starts VOYAGER CE trial of Encantor heart valve system for aortic stenosis

PUBT·11/19/2026 14:05:04
Listen to the news
Abbott starts VOYAGER CE trial of Encantor heart valve system for aortic stenosis
  • Abbott initiated VOYAGER CE to evaluate its investigational Encantor software-guided, balloon-expandable heart valve system for symptomatic severe aortic stenosis.
  • The trial will enroll up to 300 patients in Europe and Australia to support applications for regulatory approval in those markets.
  • Early feasibility findings supported the trial's initiation.
  • Six-month safety and valve performance results from the feasibility study will be presented Nov. 22 at PCR London Valves 2026.
  • A pivotal U.S. trial is planned in the coming months; Encantor would complement the existing Navitor self-expanding valve platform if approved.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbott Laboratories published the original content used to generate this news brief via PR Newswire (Ref. ID: CG02281) on November 19, 2026, and is solely responsible for the information contained therein.